Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 2Lymphoma, AIDS-Related 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 25Bevacizumab 18Paclitaxel 17Pemetrexed 16Erlotinib Hydrochloride 14Radiotherapy 12Docetaxel 9Gemcitabine 7Cisplatin 6ceritinib 5Taxes 5Cetuximab 5pembrolizumab 3pegfilgrastim 3capmatinib 3Surgical Procedures, Operative 3Radiosurgery 3Metformin 3Gefitinib 3Cyclophosphamide 3Thalidomide 2Sorafenib 2Radiotherapy, Conformal 2Nivolumab 2Immunoglobulin G 2Filgrastim 2Disulfides 2Albumin-Bound Paclitaxel 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma of Lung × pegylated granulocyte colony-stimulating factor × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡